BREA, Calif., Aug. 27, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") today announced that the company will participate in the Baird 2024 Global Healthcare Conference on Wednesday, September 11, 2024 from 10:50 – 11:20 am ET at the InterContinental New York Barclay. There will be no recording link available for this event. ABOUT ENVISTA HOLDINGS CORPORATION Envista is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr, united by ...

Did you analyze how Envista (NVST) fared in its international operations for the quarter ending June 2024? Given the widespread global presence of this maker of dental products, scrutinizing the trends in international revenues becomes imperative to assess its financial strength and future growth possibilities. In the current global economy, which is more interconnected than ever, a company's success in penetrating international markets is crucial for its financial health and growth journey. Investors must ...

Envista Holdings Corporation (NVST) reported adjusted earnings per share (EPS) of 11 cents for secondquarter 2024, down 74.4% year over year. The bottom line missed the Zacks Consensus Estimate by 59.3%. The adjustments include a $1.15 billion non-cash charge related to the impairment of goodwill and intangible assets, charges and benefits related to the amortization of acquired intangible assets and restructuring costs, among others. The company's GAAP loss was $6.69 compared with the year-ago quarter's ea ...

财务数据和关键指标变化 - 公司在第二季度实现销售收入6.33亿美元,调整后核心销售下降3.2% [32] - 公司调整后毛利率为54.2%,同比下降370个基点,主要受销量下降、产品结构不利以及Spark制造技术投资的影响 [39] - 公司调整后EBITDA利润率为10%,同比下降910个基点,主要受一次性成本、Spark递延收入以及经销商库存调整的影响 [40] - 公司第二季度调整后每股收益为0.11美元,上年同期为0.43美元 [41] - 公司第二季度自由现金流为8630万美元,同比增长41% [41] 各条业务线数据和关键指标变化 - 特殊产品与技术业务核心销售增长0.9%,正畸业务中Spark销售增长但递延收入增加,种植体业务低单位数下降 [49][50] - 设备及耗材业务核心销售下降10.1%,诊断业务高单位数下降,耗材业务受经销商库存调整影响双位数下降 [52][53] 各个市场数据和关键指标变化 - 发达市场销售中单位数下降,主要受Spark递延收入和经销商库存调整影响,剔除这些影响后小幅增长 [37] - 新兴市场销售小幅增长,俄罗斯高双位数增长,中国小幅下降 [38] 公司战略和发展方向及行业竞争 - 公司正在采取多项措施改善业绩,包括加强管理团队、提升Spark制造效率、调整经销商库存等 [16][58-67] - 公司预计第四季度将恢复增长,全年指引为负1%至负4%的核心销售增长和10%-12%的调整EBITDA利润率 [17][74] - 公司认为种植体业务是重点发展领域,正在加大在销售、营销和研发方面的投入 [135-149] 管理层对经营环境和未来前景的评论 - 公司认为牙科行业长期增长前景良好,但2024年受到宏观环境影响出现短期波动 [23][76] - 公司认为自身基础良好,有望通过各项改善措施提升业绩,恢复增长势头 [12-15][160-161] 其他重要信息 - 公司在第二季度录得12亿美元的商誉和无形资产减值 [30-31] - 公司宣布任命新任首席财务官、Nobel Biocare和正畸业务总裁 [59-68] 问答环节重要的提问和回答 问题1 **Elizabeth Anderson 提问** 询问公司的实际经营业绩水平 [79-84] **Paul Keel 回答** 解释公司的实际业绩水平,并表示有望通过各项措施改善业绩 [81-84] 问题2 **Erin Wright 提问** 询问公司对行业长期增长前景的看法,以及短期内恢复增长的计划 [90-93] **Paul Keel 回答** 表示公司对行业长期增长前景保持乐观,短期内恢复增长主要依靠内部改善措施,而非依赖宏观环境改善 [91-93] 问题3 **Jon Block 提问** 询问公司种植体业务的发展计划 [100-103] **Paul Keel 回答** 表示公司正在加大对种植体业务的投入,有望通过改善表现赶上市场增长步伐 [101-103]

Envista (NVST) reported $633.1 million in revenue for the quarter ended June 2024, representing a year-overyear decline of 4.4%. EPS of $0.11 for the same period compares to $0.43 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $647.99 million, representing a surprise of -2.30%. The company delivered an EPS surprise of -59.26%, with the consensus EPS estimate being $0.27. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street ...

Envista (NVST) came out with quarterly earnings of $0.11 per share, missing the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.43 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of -59.26%. A quarter ago, it was expected that this maker of dental products would post earnings of $0.31 per share when it actually produced earnings of $0.26, delivering a surprise of -16.13%. Over the last four quarters, ...

财务业绩 - 公司在2024年上半年录得净亏损11.28亿美元，主要由于商誉和无形资产减值11.54亿美元[19] - 公司2024年上半年调整后营业利润为1.29亿美元，调整后营业利润率为10.3%[28] - 公司2024年上半年经营活动产生的现金流为1.334亿美元[19] - 公司2024年上半年自由现金流为1.156亿美元[20] - 公司2024年第二季度销售收入为6.331亿美元，同比下降4.4%[23] - 公司2024年第二季度调整后毛利率为54.2%，同比下降3.7个百分点[27] - 公司2024年第二季度调整后营业利润为0.514亿美元，调整后营业利润率为8.1%[28] - 公司2024年第二季度调整后每股收益为0.11美元[20] - 公司净亏损11.52亿美元，主要由于商誉和无形资产减值11.54亿美元[41] - 调整后净收入为1850万美元，调整后每股收益为0.11美元[32,33] - 调整后EBITDA为6300万美元，占销售额10%[35] - 经营活动产生的现金流为1.33亿美元，自由现金流为1.16亿美元[40] 业务表现 - 专业产品与技术业务2024年上半年调整后营业利润为0.998亿美元，调整后营业利润率为12.1%[29] - 设备与耗材业务2024年上半年调整后营业利润为0.816亿美元，调整后营业利润率为18.8%[30] - 核心销售额下降3.2%，主要受到汇率影响[36] - 特殊产品和技术业务核心销售额增长0.9%[37] - 设备和耗材业务核心销售额下降10.1%[39] 非GAAP指标 - 公司剔除非经常性项目后的财务数据更能反映其经营业绩[49,50] - 公司通过调整后的财务指标帮助投资者了解其长期盈利趋势和收入增长情况[49] - 公司使用调整后EBITDA评估经营业绩并与同行业公司进行比较[49] - 公司使用非GAAP指标来评估运营和财务表现，包括调整后毛利、调整后营业利润、调整后净收入、调整后每股收益和调整后EBITDA[51] - 公司排除了收购相关和其他无形资产摊销费用，因为收购的时间、规模、数量和性质会显著影响这些费用[51] - 公司排除了一些不一致发生的项目，因为它们的性质和/或规模可能会掩盖潜在的业务趋势[52] - 公司排除了收购和已停产产品线的影响、汇率变动的影响来计算核心销售额，以更好地反映公司的持续经营情况[53] - 公司调整了经营活动现金流以扣除资本支出，得到自由现金流[54]

Analysts on Wall Street project that Envista (NVST) will announce quarterly earnings of $0.27 per share in its forthcoming report, representing a decline of 37.2% year over year. Revenues are projected to reach $647.99 million, declining 2.2% from the same quarter last year. Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 4.2% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period. ...

BREA, Calif., July 15, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) today announced the following key leadership appointments:Eric Hammes joins Envista as Chief Financial OfficerStefan Nilsson joins Envista as President, Nobel BiocareVeronica Acurio joins Envista as President, Ormco"It is a pleasure to welcome this trio of successful leaders to Envista," said Paul Keel, Chief Executive Officer. "Each brings experience in dental along with a proven track record of continuous improvement, le ...

BREA, Calif., July 12, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") will report financial results for its second quarter 2024 on Wednesday, August 7, 2024. Envista will discuss these results on a conference call on the same day beginning at 2:00 PM PT and lasting approximately one hour. The call and the accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com. A replay of the webcast will be available shortly after the c ...